<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691247</url>
  </required_header>
  <id_info>
    <org_study_id>CLBS03-P01</org_study_id>
    <nct_id>NCT02691247</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)</brief_title>
  <official_title>A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal Regulatory T-cells) in Adolescents With Recent Onset Type 1 Diabetes Mellitus (T1DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caladrius Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanford Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Caladrius Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will explore the safety and effect of autologous ex vivo expanded
      polyclonal regulatory T-cells on beta cell function in patients, aged 8 to 17, with recent
      onset T1DM. Other measures of diabetes severity and the autoimmune response underlying T1DM
      will also be explored. Eligible subjects will receive a single infusion of CLBS03 (high or
      low dose) or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mixed Meal Tolerance Test (MMTT)-stimulated C-peptide area under the curve (AUC)</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MMTT-stimulated C-peptide AUC</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin A1c (HbA1c)</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin usage</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with adverse events</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CLBS03 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLBS03 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single infusion of placebo, consisting of the infusion solution only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLBS03 Low Dose</intervention_name>
    <arm_group_label>CLBS03 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CLBS03 High Dose</intervention_name>
    <arm_group_label>CLBS03 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females aged 8 to 17 years of age

          -  Diagnosis of T1DM within 100 days of receipt of study drug

          -  Positive for at least one islet cell autoantibody

          -  Peak MMTT-stimulated C-peptide level &gt; 0.2 pmol/mL (at the screening visit)

          -  Weight of ≥30 kg

          -  Must agree to use a reliable and acceptable method of contraception for the duration
             of participation

          -  Willing and medically acceptable to postpone live vaccine immunizations for one year
             after infusion

          -  Written informed consent and written assent

        Exclusion Criteria:

          -  Hemoglobin less than the lower limit of normal

          -  Leukocytes &lt;3,000/μL; neutrophils &lt;1,500/μL; lymphocytes &lt;800/μL; platelets
             &lt;100,000/μL

          -  Regulatory T-cells present in peripheral blood at &lt;20 cells per μL

          -  Current or ongoing use of non-insulin pharmaceuticals (that may affect glycemic
             control)

          -  Current or anticipated use of systemic corticosteroids or other immunomodulatory
             drugs

          -  Recent serious bacterial, viral, fungal, or other opportunistic infections

          -  History of malignancy or serious uncontrolled cardiovascular, nervous system,
             pulmonary, renal, or gastrointestinal disease

          -  Serologic evidence of current or past viral infection: human immunodeficiency virus
             (HIV), Hepatitis B, Hepatitis C, and human T-lymphotropic virus (HTLV) 1/2

          -  Positive QuantiFERON® tuberculosis (TB) test, purified protein derivative (PPD) skin
             test, history of tuberculosis, or active TB infection

          -  Active infection with Epstein-Barr Virus or Cytomegalovirus

          -  Liver disease

          -  Pregnant or breast-feeding

          -  Vaccination with a live virus within 8 weeks of receipt of study drug

          -  Vaccination with a killed virus within 2 weeks of receipt of study drug

          -  Participation in an investigational drug study within 90 days prior to screening

          -  Previously treated with a T-Reg based cell therapy

          -  History of allergy to gentamicin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Losordo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Caladrius Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Kotynski</last_name>
    <email>ckotynski@caladrius.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judy Matarese</last_name>
    <email>jmatarese@caladrius.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Rodriguez</last_name>
      <phone>415-476-5026</phone>
      <email>tracy.rodriguez@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen E. Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruthie Williamson</last_name>
      <phone>303-724-6894</phone>
      <email>Ruthie.Williamson@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maya Barr</last_name>
      <phone>303-724-8594</phone>
      <email>Mayalin.Barr@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naomi Yama, RN</last_name>
      <phone>203-737-2737</phone>
    </contact>
    <contact_backup>
      <last_name>Linda Rink</last_name>
      <phone>203-737-4510</phone>
      <email>linda.rink@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevan C. Herold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Cintron</last_name>
      <phone>352-273-5580</phone>
      <email>cintrm@peds.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Turnier</last_name>
      <phone>352-273-5275</phone>
      <email>melissa.turnier@peds.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael J. Haller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami, Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della Matheson</last_name>
      <phone>305-243-3781</phone>
      <email>dmatheso@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>David A. Baidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Mullen</last_name>
      <phone>317-278-7036</phone>
      <email>maamulle@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Woerner</last_name>
      <phone>317-944-2573</phone>
      <email>sestein@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Linda DiMeglio, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Resnick</last_name>
      <phone>888-813-8669</phone>
      <email>brittany.resnick@joslin.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Gaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Clark, RN</last_name>
      <phone>816-760-5592</phone>
      <email>akclark@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Mark A. Clements, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn McEvoy</last_name>
      <phone>701-234-3722</phone>
      <email>kathryn.mcevoy@sanfordhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Spitzer</last_name>
      <phone>701-234-7258</phone>
      <email>natalie.spitzer@sanfordhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Luis Casas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fitch</last_name>
      <phone>503-494-4739</phone>
      <email>fitch@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Jahnke</last_name>
      <phone>503-494-4704</phone>
      <email>jahnkekr@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ines Guttmann-Bauman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Huber</last_name>
      <phone>605-328-1392</phone>
      <email>christina.huber@sanfordhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan Broadbent</last_name>
      <phone>605-328-8742</phone>
      <email>megan.broadbent@sanfordhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Griffin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eskind Diabetes Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faith Brendle</last_name>
      <phone>615-875-6150</phone>
      <email>faith.brendle@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jordan Smith</last_name>
      <phone>615-936-6324</phone>
      <email>tyler.j.smith@vanderbilt.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>February 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1DM</keyword>
  <keyword>Type 1 Diabetes Mellitus</keyword>
  <keyword>T regulatory cell</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>T-Reg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
